Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll The Mount Sinai conference on the pharmacotherapy of schizophrenia Marder SR; Essock SM; Miller AL; Buchanan RW; Davis JM; Kane JM; Lieberman J; Schooler NRSchizophr Bull 2002[]; 28 (1): 5-16This report summarizes the recommendations from a consensus meeting that focused on specific questions regarding the pharmacotherapy of schizophrenia. The issues were selected because there was evidence that experts had recently disagreed about the evidence supporting a particular practice or when there were substantial variations in a clinical practice indicating that there was disagreement among clinicians. The group of experts was able to reach a consensus regarding the evidence base pertaining to the following issues: First generation (FGAs) and second generation (SGAs) antipsychotics as first line agents; the duration of antipsychotic trials; the effectiveness of clozapine and other agents for treatment refractory schizophrenia; risk of tardive dyskinesia on FGAs and SGAs; differences among antipsychotics for different dimensions of psychopathology; and side effect monitoring for various antipsychotics.|*Schizophrenic Psychology[MESH]|Antipsychotic Agents/adverse effects/classification/*therapeutic use[MESH]|Critical Pathways[MESH]|Dyskinesia, Drug-Induced/etiology[MESH]|Evidence-Based Medicine[MESH]|Humans[MESH]|Risk Factors[MESH]|Schizophrenia/*drug therapy[MESH]|Treatment Outcome[MESH] |